{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:10:56Z","timestamp":1745554256619,"version":"3.40.4"},"reference-count":12,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2004]]},"abstract":"<i>Purpose:<\/i> Two isoforms of cyclooxygenase (COX-1 and COX-2) exist. To determine in vivo effects of the intravenous administration of FR122047 (a selective COX-1 inhibitor), FR188582 (a selective COX-2 inhibitor), diclofenac sodium or dexamethasone phosphate disodium on prostaglandin-E<sub>2<\/sub> (PGE<sub>2<\/sub>)-induced aqueous flare elevation and mRNA levels for COX-1 and COX-2 in pigmented rabbits. <i>Methods:<\/i> To produce aqueous flare elevation in rabbits, PGE<sub>2<\/sub>, 25 \u00b5g\/ml, was applied to the cornea with the use of a glass cylinder. FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium was intravenously injected before PGE<sub>2<\/sub> application. Aqueous flare was measured with a laser flare-cell meter. The mRNA levels for COX-1 and COX-2 in the iris-ciliary body were determined by real-time polymerase chain reaction. <i>Results:<\/i> FR122047, FR188582 and diclofenac sodium (15 \u00b5mol\/kg each) injected intravenously 30 min before PGE<sub>2<\/sub> application inhibited 29 \u00b1 5, 40 \u00b1 12 and 50 \u00b1 9% of aqueous flare elevation, respectively. Simultaneous injection of FR122047 (15 \u00b5mol\/kg) and FR188582 (15 \u00b5mol\/kg) 30\u00a0min before PGE<sub>2<\/sub> application inhibited 61 \u00b1 8% of flare elevation. Dexamethasone phosphate disodium (15\u00a0\u00b5mol\/kg) injected intravenously 300 min before PGE<sub>2<\/sub> application inhibited 68 \u00b1 8% of aqueous flare elevation. Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE<sub>2<\/sub>, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment. <i>Conclusion:<\/i> It is possible that enzyme activities of both COX-1 and COX-2 may be involved in the mechanism of PGE<sub>2<\/sub>-induced aqueous flare elevation in pigmented rabbits.<\/jats:p>","DOI":"10.1159\/000081634","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T10:00:23Z","timestamp":1104400823000},"page":"321-326","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Intravenous Administration of FR122047 (a Selective Cyclooxygenase 1 Inhibitor) and FR188582 (a Selective Cyclooxygenase 2 Inhibitor) on Prostaglandin-E<sub>2<\/sub>-Induced Aqueous Flare Elevation in Pigmented Rabbits"],"prefix":"10.1159","volume":"36","author":[{"given":"Tomohiro","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriko","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,12,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159%2F000267895"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000074074"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0006-2952%2802%2901422-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146%2Fannurev.pharmtox.38.1.97"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2FS0014-2999%2800%2900051-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjp.0704511"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1254%2Fjjp.85.175"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1006%2Fexer.2001.0977"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI118717"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.272.41.25693"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038%2Flabinvest.3780017"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2FS0006-2952%2897%2900018-X"}],"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:46:31Z","timestamp":1745466391000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000081634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2004,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000081634","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"type":"print","value":"0030-3747"},{"type":"electronic","value":"1423-0259"}],"subject":[],"published":{"date-parts":[[2004]]}}}